William Nathaniel Brennen, Ph.D.
Prostate Cancer; Therapy; Tumor Microenvironment; Fibroblasts; MSCs; prodrugs; Stroma ...read more
WN Brennen, JT Isaacs, SR Denmeade, Rationale behind targeting fibroblast activation protein–expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Molecular cancer therapeutics 11 (2), 257-266
WN Brennen, DM Rosen, H Wang, JT Isaacs, SR Denmeade, Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. Journal of the National Cancer Institute 104 (17), 1320-1334
Y Zhu, SL Dalrymple, I Coleman, SL Zheng, J Xu, JE Hooper, et al. Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors. Oncogene 39 (45), 6935-6949
WN Brennen, Y Zhu, IM Coleman, SL Dalrymple, L Antony, RA Patel, et al. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer. JCI insight 6 (8)
TEG Krueger, DLJ Thorek, SR Denmeade, JT Isaacs, WN Brennen. Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise. Stem cells translational medicine 7 (9), 651-663
Patient Ratings & Comments
The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.